Target
T790M
1 abstract
Abstract
BLU-945 monotherapy and in combination with osimertinib (OSI) in previously treated patients with advanced EGFR-mutant (EGFRm) NSCLC in the phase 1/2 SYMPHONY study.Org: Blueprint Medicines, Sarah Cannon Research Institute/Tennessee Oncology, Perlmutter Cancer Center, New York University Langone Health, Gustave Roussy, Department of Medical Oncology, Thoracic Group,